Navigation Links
Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
Date:4/17/2012

BOSTONAdding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) an approach approved by the FDA in 2006 did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

The study is being published in the April 18 Journal of the American Medical Association, a these issue on comparative effectiveness research.

"Effectiveness research examines the impact of treatments when they are used in day-to-day practice in ordinary circumstances," says the study's senior author, Deborah Schrag, MD, MPH, of Dana-Farber. "First, we found that bevacizumab was not universally adopted after its FDA approval. Second, the addition of bevacizumab did not provide any substantial survival advantage when added to standard chemotherapy."

Schrag will present the findings at a JAMA media briefing at the National Press Club in Washington on Tuesday, Apr. 17, 9:15 am. A separate video commentary is available on request.

A previous trial found that adding bevacizumab to the standard two-drug treatment for NSCLC the chemotherapy agents carboplatin and paclitaxel improved survival in many patients with advanced cases of the disease, but not those aged 65 years or older, the study authors write. In the new study, Schrag and her colleagues measured survival rates in patients who received bevacizumab-carboplatin-paclitaxel therapy and in two groups of patients who received carboplatin-paclitaxel therapy one group receiving it in 2006-2007, the other in 2002-2005.

They found that the median overall survival was 9.7 months for patients receiving the three-drug combination compared with 8.9 months for the 2006-2007 standard-therapy group, and 8.0 months for the 2002-2005 standard-therapy group. The probability of surviving for one year was 39.6 percent for those who received the three drugs vs. 40.1 percent for the 2006-2007 standard-therapy group, and 35.6 percent for the 2002-2005 standard-therapy group. Controlling for factors that can skew the results, the authors did not find a significant difference in overall survival between patients treated with bevacizumab and those treated only with standard chemotherapy.

Based on these results, the authors recommend that bevacizumab should not automatically be administered together with carboplatin-paclitaxel for older patients with NSCLC. They continue that clinicians should exercise caution in making treatment recommendations and use bevacizumab judiciously for their patients.

The authors also advise that for cancers like NSCLC that tend to arise in elderly patients, clinical trials of potential new therapies should include an adequate number of older patients and ensure that data for these patients is analyzed.


'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Twitter Adding to Stigma of Epilepsy, Study Says
2. Adding Lovenox Didnt Reduce Blood Clot Death Risk in Study
3. Adding Psychotherapy to Meds Helps Kids With OCD
4. Heart Attack Damage Not Reduced by Adding Balloon Pump to Angioplasty
5. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
6. Adding a stent during minimally invasive surgery to repair aneurysms prevents recurrence
7. Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux
8. Adding Folate to Tortilla Flour Might Cut Birth Defects Among Hispanics
9. Breast cancer surgery patients benefit from adding radiation therapy
10. Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
11. Adding Surgery to Meds May Help Diabetics With Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... San Rafael, CA (PRWEB) , ... May 26, ... ... Studio will be offering campers a multitude of activities from daily practices, arts ... and self-confidence. , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds ...
(Date:5/26/2016)... ... , ... Bunion Bootie , the manufacturer of the newest and best ... by customer demand over the Mother’s Day Weekend promotion. So much so, that they ... has completely replenished its inventory levels, it hopes to continue its current sales pace, ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... organization to provide strategic sales leadership and to further develop their rapidly expanding ... B.S. in Business Administration with a concentration in Marketing and an M.B.A. with ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... announce the launch of its brand equity product, Brandvantage. This breakthrough tool ... dynamic landscape of modern consumer decision-making. The proprietary framework incorporates attitudes, behavior ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... announce that it has successfully completed another Health Canada inspection and has received ... Canada. The rating resulted from a Good Manufacturing Practices (GMP) inspection conducted at ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25, 2016 According to ... Development, Growth and Demand Forecast to 2022 - Industry ... and Others)" published by P&S Market Research, the global ... in 2015, and it is expected to grow at ... the insulin pump segment is expected to witness the ...
(Date:5/25/2016)... 25, 2016 Inivata, a ... of circulating tumour DNA (ctDNA) analysis to improve ... of Professor Clive Morris as Chief ... the clinical development programme, scientific collaborations, and through ... significant improvements in clinical outcomes for patients. ...
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
Breaking Medicine Technology: